Latest & greatest articles for Antithyroid Drug

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Antithyroid Drug or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Antithyroid Drug and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Antithyroid Drug

1. Risk factors for the relapse of Graves' disease treated with antithyroid drugs: a systematic review and meta-analysis

Risk factors for the relapse of Graves' disease treated with antithyroid drugs: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) characteristics (e.g. species, sex or drug class or dose) and effect size. They should be considered hypothesis-generating. Ideally, a threshold describing the number of studies per subgroup required for analysis should be specified. For further guidance please refer to the and to pre-clinical meta-analysis. Example: The following study characteristics will be examined as potential source of heterogeneity: species (stratified per species); sex (stratified per sex); duration of index ischemia (linear); stem

2019 PROSPERO

2. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. (PubMed)

Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Untreated or insufficiently treated Graves disease in pregnancy may pose risks to both mother and fetus. Antithyroid drugs (ATDs) are the treatment mainstay, but the potential teratogenic effect of these drugs has prompted clinicians to question the safe management of this vulnerable population.To examine the association between maternal prescriptions for ATDs and congenital malformations in live births.Nationwide

2018 Annals of Internal Medicine

3. Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? (PubMed)

Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? Resistance to thyroid hormone β (RTHβ) due to homozygous THRB defects is exceptionally rare, with only five kindreds reported worldwide. Cardiac dysfunction, which can be life-threatening, is recognized in the disorder. Here we describe the clinical, metabolic, ophthalmic, and cardiac findings in a 9-year-old boy harboring a biallelic THRB mutation (R243Q (...) and cardiac function. A combination of antithyroid drug and TRIAC therapy may prevent thyrotoxic cardiomyopathy and its decompensation in homozygous or even heterozygous RTHβ in which life-threatening hyperthyroid features predominate.

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

4. Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy

Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy Prescrire IN ENGLISH - Spotlight ''Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy '', 1 March 2017 {1} {1} {1} | | > > > Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy FEATURED REVIEW Graves' disease is the most frequent cause of hyperthyroidism. What is the best treatment for adults with Graves' disease? To answer this question, we reviewed the literature using the standard Prescrire methodology. Full review (6 pages) available for download by subscribers. Abstract What is the best treatment for adults with Graves

2017 Prescrire

5. Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report (PubMed)

Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report Graves thyrotoxicosis rarely presents with painless jaundice resulting from hyperthyroidism-associated hepatotoxicity, without preexisting liver disease. Management in patients with this presentation is challenging, given that the thionamides, methimazole and propylthiouracil, have both been associated with drug-induced liver injury. Radioactive iodine ablation and thyroidectomy are well

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

6. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. (PubMed)

Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. To determine the effect of adjunctive antithyroid drugs on the risk of treatment failure, hypothyroidism, and adverse events after radioiodine treatment.Meta-analysis.Electronic databases (Cochrane central register of controlled trials, Medline, Embase) searched to August 2006 and contact with experts. Review methods Three reviewers independently assessed trial eligibility (...) and quality. Pooled relative risks for treatment failure and hypothyroidism after radioiodine treatment with and without adjunctive antithyroid drugs were calculated with a random effects model.We identified 14 relevant randomised controlled trials with a total of 1306 participants. Adjunctive antithyroid medication was associated with an increased risk of treatment failure (relative risk 1.28, 95% confidence interval 1.07 to 1.52; P=0.006) and a reduced risk for hypothyroidism (0.68, 0.53 to 0.87; P

Full Text available with Trip Pro

2007 BMJ

7. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

8. Antithyroid drug regimen for treating Graves' hyperthyroidism. (PubMed)

Antithyroid drug regimen for treating Graves' hyperthyroidism. Antithyroid drugs are widely used in the therapy of hyperthyroidism. There are wide variations in the dose, regimen or duration of treatment used by health professionals.To assess the effects of dose, regimen and duration of antithyroid drug therapy for Graves' hyperthyroidism.We searched the Cochrane Central Register of Controlled Trials (Central), MEDLINE, EMBASE, BIOSIS, CINAHL, HEALTHSTAR, Current Controlled Trials and reference (...) to 1.10). Participants reporting rashes (11% versus 5%) and withdrawing due to side effects (16% versus 9%) were significantly higher in the Block-Replace group compared to the Titration group respectively. Three studies considered the addition of thyroxine after initial therapy with antithyroid drugs. There was significant heterogeneity between the studies and the difference between the two groups were not significant (Odds ratio = 0.58, 95% CI 0.05 to 6.21).The evidence (based on three studies

2003 Cochrane

9. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study

Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized (...) were an antithyroid drug plus thyroxine combination, subtotal thyroidectomy, and iodine-131. Those patients aged 20 to 34 years received either the antithyroid drug plus thyroxine combination (young medical group), or subtotal thyroidectomy (young surgical group). Those patients aged 35 to 55 years received either the antithyroid drug plus thyroxine combination (old medical group), subtotal thyroidectomy (old surgical group), or iodine-131 (iodine-131 group). Type of intervention Treatment

1998 NHS Economic Evaluation Database.

10. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. (PubMed)

Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. Antithyroid drugs are effective in patients with hyperthyroidism due to Graves' disease, but the rate of recurrence after treatment is high. In a recent Japanese study, adjunctive treatment with thyroxine (T4) was associated with a recurrence rate 20 times lower than that among patients who received only an antithyroid drug. If these results are confirmed, combined therapy (...) with an antithyroid drug and T4 might become the treatment of choice for all patients with Graves' hyperthyroidism.We treated 111 patients (89 women and 22 men) who had Graves' hyperthyroidism. All patients initially received 40 mg of carbimazole daily for one month. Then one group received carbimazole alone for 17 months (52 patients), and the other group received carbimazole plus T4 for 17 months and T4 alone for 18 months (59 patients). In the carbimazole group, the dose was adjusted after one month

1996 NEJM Controlled trial quality: uncertain

11. Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. (PubMed)

Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. To assess the value of antithyroid drugs as an adjunct to radioactive iodine for the treatment of hyperthyroidism the incidence of relapse or hypothyroidism after a mean follow-up of 5 1/2 years (range 2-7 years) was reviewed retrospectively for 206 patients, some treated with and others without antithyroid drugs after radioiodine therapy. Allocation to treatment group had been random (...) , and both groups were similar in all respects except for the adjunctive treatment with antithyroid drugs. All doses of 131I had been calculated by one physician. Compared with those who received 131I alone, those starting on antithyroid drugs within 8 days after 131I had a lower incidence of hypothyroidism but a higher incidence of early post-treatment recurrence or persistence of hyperthyroidism, and a considerably lower incidence of remission.

1988 Lancet Controlled trial quality: uncertain